Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03570476 · ClinicalTrials.gov registry record · Phase 2
Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT03570476: Clinical Trial Phase 2 study, sponsored by University of Washington.
NCT03570476 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03570476, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase II trial studies how well olaparib works in treating participants with prostate cancer that has not spread to other parts of the body (localized). Olaparib may stop the growth of tumor cells by interfering with the activity of a substance called PARP, which is inside cells. Giving olaparib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Primary Outcome
Percent of patients who achieve a pCR at the time of prostatectomy, after 12 weeks of neoadjuvant therapy with olaparib. PCR is defined as the absence of morphologically identifiable carcinoma in the prostatectomy specimen. Assessment will be based on the recommendations of the International Society of Urological Pathology (ISUP).
Interventions
- DRUG Olaparib
- PROCEDURE Radical Prostatectomy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-09-11 |
| Est. Completion | 2019-07-03 |
| Phase | Phase 2 |
Why NCT03570476 stopped before completion
NCT03570476 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Olaparib is the first listed.
NCT03570476 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03570476 about?
NCT03570476 is a clinical study titled "Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer". This phase II trial studies how well olaparib works in treating participants with prostate cancer that has not spread to other parts of the body (localized). Olaparib may stop the growth of tumor cells by interfering with the activity of a substance called PARP, which is inside cells. Giving olapari...
What is the current status of trial NCT03570476?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2018-09-11. Estimated completion is 2019-07-03.
What interventions are being tested in trial NCT03570476?
The interventions under investigation include: Olaparib (DRUG), Radical Prostatectomy (PROCEDURE).
Who is sponsoring clinical trial NCT03570476?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03570476's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI